CT Stress Myocardial Perfusion, Fractional Flow Reserve and Angiography in Patients With Stable Chest Pain Syndromes
DYNAMITE
DYnamic CT Stress Myocardial perfusioN, CT Fractional Flow Reserve and Coronary CT Angiography for Optimized treatMent Strategy In Patients With sTable Chest Pain syndromEs
1 other identifier
interventional
2,000
1 country
1
Brief Summary
The purpose of the DYNAMITE trial (Dynamic CT stress myocardial perfusion, CT fractional flow reserve (FFR-CT) and coronary CT angiography for optimized treatment strategy in patients with chest pain syndromes) is to determine the ability of combined anatomical and functional cardiac CT imaging to improve morbidity and mortality in patients with suspected or known ischemic heart disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable coronary-artery-disease
Started Dec 2021
Longer than P75 for not_applicable coronary-artery-disease
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 12, 2021
CompletedFirst Posted
Study publicly available on registry
January 14, 2021
CompletedStudy Start
First participant enrolled
December 3, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2031
ExpectedDecember 12, 2022
December 1, 2022
3 years
January 12, 2021
December 8, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Major Adverse Cardiovascular Events
cardiovascular death, acute myocardial infarction, stroke or hospitalization for heart failure
3 years
Secondary Outcomes (15)
Individual components of the primary endpoint
3 years
Acute myocardial infarction stratified by subtype
12 months
Hospitalization due to unstable angina pectoris, bleeding, pacemaker and/or implantable/cardioverter defibrillator implantation, surgical or percutaneous heart valve treatment
3 years
All-cause mortality
3 years
All-cause mortality
10 years
- +10 more secondary outcomes
Study Arms (2)
Intervention group
ACTIVE COMPARATORCT angiography, FFR-CT and dynamic CT stress myocardial perfusion guided treatment strategy
Standard care group
NO INTERVENTIONEvaluation and treatment strategy according to contemporary clinical practice
Interventions
The study intervention team consists of a specialist in Cardiac CT imaging, an invasive cardiologist, a thoracic surgeon and a cardiology nurse specialist. Treatment strategy defined by the study team based on CT findings involve referral for percutaneous coronary intervention, Coronary Artery Bypass surgery and/or initiation of optimal medical therapy, in addition to potential supplementary diagnostic procedures.
Eligibility Criteria
You may qualify if:
- Chest pain in patients with clinically suspected or confirmed ischemic heart disease
- Clinical indication for non-acute coronary evaluation
- Status of coronary revascularization
- With previous coronary revascularization - all patients
- Without previous coronary revascularization
- Age≥65 years - all patients with chest pain
- Age\>50 - \<65 years - typical angina pectoris and at least one cardiovascular risk factor and/or previous myocardial infarction
- Typical angina requiring all 3 criteria present: a) constrictive discomfort in the front of the chest or in the neck, jaw, shoulder or arm, b) precipitated by physical exertion c) relieved by rest or nitrates within 5 min.
- Cardiovascular risk factors: hypertension, diabetes, hypercholesterolemia, current smoking, family history of ischemic heart disease, previous stroke, peripheral artery disease
You may not qualify if:
- Persistent chest pain and signs of ongoing acute myocardial ischemia requiring acute coronary intervention
- Hospitalization and discharge with the confirmed diagnosis acute coronary syndrome (STEMI or NSTEMI) within the last 6 months
- Severe valvular heart disease as primary diagnosis and/or in potential need of percutaneous or surgical valve treatment
- Known severe heart failure (LVEF less than 35%)
- Language, cultural or mental factors preventing the patient from understanding the informed consent form
- Known atrial fibrillation
- Known renal impairment (estimated Glomerular Filtration Rate below \<30 ml/min)
- Known x-ray contrast allergy
- Known intolerance to adenosine infusion
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Cardiology and Radiology, Rigshospitalet, The Heart Center, Capital Region of Copenhagen, University of Copenhagen
Copenhagen, 2100, Denmark
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Klaus F Kofoed, MD
Department of Cardiology, Rigshospitalet, University of Copenhagen, Denmark
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Clinical associated Research Professor
Study Record Dates
First Submitted
January 12, 2021
First Posted
January 14, 2021
Study Start
December 3, 2021
Primary Completion
December 1, 2024
Study Completion (Estimated)
December 1, 2031
Last Updated
December 12, 2022
Record last verified: 2022-12
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP
- Time Frame
- Statistical Analysis Plan and study protocol a time of publication
- Access Criteria
- Curated by principle investigator according to contemporary law
Following publication of the main results of the trial, anonymized data will be made available to other researchers through the Zenodo open data repository.